The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Functional Characterization and Multimodal Imaging of Treatment-Naïve “Quiescent” Choroidal Neovascularization
Open accessAbstract
PURPOSE: To investigate the multimodal morphological and functional characteristics of treatment-naïve "quiescent" choroidal neovascularization (CNV) secondary to AMD. METHODS: Eleven patients with treatment-naïve "quiescent" CNV that consecutively presented over a 6-month period, underwent multimodal morphological and functional assessment (including indocyanine green angiography [ICGA], spectral-domain optical coherence tomography [SD-OCT], microperimetry, and preferential hyperacuity perimeter [PHP]). For the purpose of this study, asymptomatic previously untreated CNVs showing absence of intraretinal/subretinal exudation in two consecutive visits (at least 6 months apart) were defined as treatment-naïve "quiescent" CNV. RESULTS: Eleven eyes of 11 patients (9 females; mean age 76.5 ± 8.5 years) were included. On fluorescein angiography (FA), "quiescent" CNVs appeared as late speckled hyperfluorescent lesions lacking well-demarcated borders. Mid-late phase ICGA allowed visualizing the hyperfluorescent "quiescent" CNV network and delineating the plaque. Mean lesion area (mid-late phase ICGA) appeared larger compared with earliest previous examination performed 23.8 ± 16.0 months before (3.24 ± 2.51 mm(2) vs. 3.52 ± 2.46 mm(2), respectively; P = 0.01). SD-OCT revealed, at the site of "quiescent" CNV, an irregularly slightly elevated RPE, without hyporeflective intraretinal/subretinal fluid, showing a major axis in the horizontal plane, which was characterized by collections of moderately reflective material in the sub-RPE space and clear visualization of the hyperreflective Bruch's membrane. Hypergeometric distribution revealed a significant correlation between microperimetry and PHP with respect to locations of "affected areas" (P = 0.001). CONCLUSIONS: "Quiescent" CNVs are sub-RPE CNVs secondary to AMD, showing absence of intraretinal/subretinal exudation on repeated OCT. "Quiescent" CNVs enlarge over time and may contribute to local reduced retinal sensitivity and metamorphopsia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102673 · Cited by 2,669
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
Martin, D. F., Maguire, M. G., Fine, S. L., Ying, G.-S., Jaffe, G. J., Grunwald, J. E., Toth, C., Redford, M., & Ferris, F. L. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.03.053 · Cited by 1,715
The Natural History and Prognosis of Neovascular Age-Related Macular Degeneration
Wong, T., Chakravarthy, U., Klein, R., Mitchell, P., Zlateva, G., Buggage, R., Fahrbach, K., Probst, C., & Sledge, I. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2007.03.008 · Cited by 601
Cited by
Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data
Spaide, R. F., Jaffe, G. J., Sarraf, D., Freund, K. B., Sadda, S. R., Staurenghi, G., Waheed, N. K., Chakravarthy, U., Rosenfeld, P. J., Holz, F. G., et al. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2019.11.004 · Cited by 824
“After this report, Querques et al 32 in 2013 reported cases of neovascularization without exudation in separate examinations separated by 6 months or more and called this form quiescent neovascularization.”
Self-citationAge-related macular degeneration
Guymer, R. H., & Campbell, T. G. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02609-5 · Cited by 502
Risk factors for progression of age‐related macular degeneration
Heesterbeek, T. J., Lorés‐Motta, L., Hoyng, C. B., Lechanteur, Y. T. E., & den Hollander, A. I. (2020) · Ophthalmic and Physiological Optics · doi:10.1111/opo.12675 · Cited by 392
Mettu, P. S., Allingham, M. J., & Cousins, S. W. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100906 · Cited by 370
Joussen, A. M., Ricci, F., Paris, L. P., Korn, C., Quezada-Ruiz, C., & Zarbin, M. (2021) · Eye · doi:10.1038/s41433-020-01377-x · Cited by 290
Roisman, L., Zhang, Q., Wang, R. K., Gregori, G., Zhang, A., Chen, C.-L., Durbin, M. K., An, L., Stetson, P. F., Robbins, G., et al. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.01.044 · Cited by 261
Retinal Progression Biomarkers of Early and Intermediate Age-Related Macular Degeneration
Flores, R., Carneiro, Â., Tenreiro, S., & Seabra, M. C. (2021) · Life · doi:10.3390/life12010036 · Cited by 42
Metadata
- Authors
- Querques, G., Srour, M., Massamba, N., Georges, A., Ben Moussa, N., Rafaeli, O., & Souied, E. H.
- Venue
- Investigative Opthalmology & Visual Science
- Published
- 2013-10-21
- Volume
- 54
- Issue
- 10
- Pages
- 6886
- ISSN
- 0146-0404 (ISSN-L)
- 1552-5783
- OpenAlex
- W2092103332
- Cited by
- 165
- References
- 5
- FWCI
- 3.31
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.